Article
Medicine, General & Internal
Haixu Yu, Wei Rong, Jie Yang, Jie Lu, Ke Ma, Zhuohui Liu, Hui Yuan, Lei Xu, Yulin Li, Zhi-Cheng Jing, Jie Du
Summary: This study found that reduced plasma TRAIL levels predict short-term adverse events in normotensive patients with acute PE. The combination of TRAIL and hs-cTnI as a biomarker-based risk stratification strategy has a similar risk classification effect in normotensive patients with acute PE.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Genetics & Heredity
Atsushi Watanabe, Kunio Miyake, Koshi Akahane, Kumiko Goi, Keiko Kagami, Hideo Yagita, Takeshi Inukai
Summary: Immunotherapies specific for BCP-ALL, such as anti-CD19 CAR T-cells and blinatumomab, have significantly improved outcomes in refractory cases. The methylation status of DR4 and DR5 genes is associated with gene expression levels, cell-surface expression, and TRAIL-sensitivities, suggesting potential clinical relevance in predicting immunotherapy efficacy. Evaluating methylation status of DR4 and DR5 genes may be informative in certain cases with unfavorable karyotypes.
Article
Biotechnology & Applied Microbiology
Qiang Zhou, Jianxia Yuan, Yi Liu, Yayun Wu
Summary: Cisatracurium besilate inhibits gastric cancer cell proliferation, promotes apoptosis, increases the expression of p53 and PUMA, and enhances TRAIL-induced apoptosis. However, pifithrin-alpha can reverse the synergistic effects of cisatracurium besilate and TRAIL on AGS cell activities.
Review
Physiology
Laurel A. Grisanti
Summary: Cardiovascular disease is a leading cause of death globally. Cardiomyocyte death, which occurs in heart damage and stress, contributes to cardiac dysfunction and further damages the heart. Apoptosis, a regulated form of cell death, can occur through intrinsic or extrinsic pathways. The poorly characterized TNF-related ligand TRAIL and its receptors have been found to play a role in cardiac pathology. This article aims to provide an overview of the current understanding of TRAIL and its receptors in normal and pathological conditions in the heart.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Cell Biology
Tayyab Shahzad, Cho-Ming Chao, Stefan Hadzic, Judith Behnke, Luisa Biebach, Eva Boettcher-Friebertshaeuser, Jochen Wilhelm, Anne Hilgendorff, Klaus-Peter Zimmer, Rory E. Morty, Saverio Bellusci, Harald Ehrhardt
Summary: Hyperoxia-induced inflammation and tissue damage are crucial steps leading to BPD. TRAIL plays a protective role in lung development, and its depletion leads to structural damage.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu, Simon Sirtl, Julia Schneider, Stefan Munker, Ujjwal Mukund Mahajan, Juan Jose Montero, Joscha Griger, Julia Mayerle, Florian P. Reiter, Enrico N. De Toni
Summary: Research has identified frequent changes in BRCA genes in pancreatic cancer patients, especially in BRCA2. Pancreatic cancers with alterations in BRCA genes are sensitive to treatment with PARP inhibitors. This study shows that the combination of olaparib and TRAIL can be more effective than olaparib alone in killing pancreatic cancer cells. Furthermore, the combination of olaparib and TRAIL also kills cancer cells without BRCA2 mutations. These findings suggest a potential new combination therapy for pancreatic cancer independent of BRCA2 mutations.
Article
Medicine, Research & Experimental
Xin Xiao, Juan Xu, Xiaoan Sheng, Chao Wang, Juanjuan Dong, Xianfeng Shi
Summary: Tobacco nicotine use is a known risk factor for lung cancer, but its role in inducing drug resistance is unclear. This study found that nicotine upregulated the expression of SNHG5 and decreased caspase-3 levels, leading to TRAIL resistance in smokers with lung cancer. SNHG5 was found to interact with X-linked inhibitor of apoptosis protein, promoting TRAIL resistance. These findings demonstrate that nicotine promotes TRAIL resistance through the SNHG5/X-linked inhibitor of apoptosis protein pathway in lung cancer.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Review
Oncology
Olivia A. Diaz Arguello, Hidde J. Haisma
Summary: Cancer, a complex disease marked by evasion of apoptosis, can potentially be treated by inducing apoptosis in cancerous cells. Among the tumor necrosis factor (TNF) protein family, certain ligands possess apoptosis-inducing capabilities. Various recombinant TNF apoptosis-inducing ligands have been developed over time to improve their effectiveness in cancer treatment.
Article
Oncology
Regis Brion, Malika Gantier, Kevin Biteau, Julien Taurelle, Benedicte Brounais-Le Royer, Franck Verrecchia, Francoise Redini, Romain Guiho
Summary: Osteosarcoma and Ewing sarcoma are the most common malignant primary bone tumors in children. Triggering the TRAIL pro-apoptotic pathway shows promise in treating these tumors, but resistance mechanisms have limited its effectiveness. This study used human cell lines and xenograft models to investigate the differences in signaling pathways between TRAIL-sensitive and TRAIL-resistant cells, and proposed two strategies to overcome resistance.
Article
Chemistry, Multidisciplinary
Hyeonwoo Je, Gi-Hoon Nam, Gi Beom Kim, Wonjun Kim, Soo Rin Kim, In-San Kim, Eun Jung Lee
Summary: TRAIL shows promising anti-tumor activity, but faces challenges such as resistance and delivery issues. A nanocage has been developed to efficiently deliver TRAIL and a re-sensitizing drug (DOX) to overcome TRAIL-resistant tumors, demonstrating potential as an effective antitumor agent.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Biochemistry & Molecular Biology
Kelly Xue Jing Jong, Elsa Haniffah Mejia Mohamed, Zaridatul Aini Ibrahim
Summary: This review discusses the role of TRAIL decoy receptors in modulating TRAIL-induced apoptosis in colorectal cancer. The current available in vitro, in vivo, and human studies suggest that decoy receptors might be associated with the reduced sensitivity towards TRAIL treatment, although there are discrepancies among different research groups.
Article
Cardiac & Cardiovascular Systems
Suneela Zaigham, Magnus Dencker, Magnus K. Karlsson, Ola Thorsson, Per Wollmer
Summary: This study found that elevated TRAIL levels are associated with impaired lung function in school-aged children, especially with significant associations with markers of pulmonary airflow obstruction.
RESPIRATORY MEDICINE
(2021)
Article
Oncology
Darren C. Phillips, Fritz G. Buchanan, Dong Cheng, Larry R. Solomon, Yu Xiao, John Xue, Stephen K. Tahir, Morey L. Smith, Haichao Zhang, Deborah Widomski, Vivek C. Abraham, Nan Xu, Zhihong Liu, Li Zhou, Enrico DiGiammarino, Xin Lu, Nandini Rudra-Ganguly, Bruce Trela, Susan E. Morgan-Lappe
Summary: This study highlights the activity of a hexavalent TRAIL-receptor agonistic fusion protein in preclinical models of solid tumors, distinguishing it mechanistically from other TRAIL-based therapeutics.
Review
Cardiac & Cardiovascular Systems
Na Kuang, Bingjun Shu, Fengjing Yang, Song Li, Mingxi Zhang
Summary: This meta-analysis found that decreased TRAIL levels were negatively associated with all-cause mortality, while increased TRAIL-R2 levels were positively associated with all-cause mortality, CV mortality, myocardial infarction, and new-onset heart failure.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2023)
Article
Microbiology
Sukumar Pal, Sydni Sheff, Mufadhal Al-Kuhlani, David M. Ojcius, Luis M. de la Maza
Summary: TRAIL-R does not appear to play a major role in the susceptibility, clinical outcomes, or long-term sequelae of C. muridarum infections.
MICROBIOLOGY SPECTRUM
(2022)
Article
Clinical Neurology
Atefeh Entezari, Mahmoud Shekari Khaniani, Tayyeb Bahrami, Sima Mansoori Derakhshan, Hossein Darvish
NEUROLOGICAL SCIENCES
(2017)
Review
Medicine, Research & Experimental
Adel Naimi, Ali Akbar Movassaghpour, Majid Farshdousti Hagh, Mehdi Talebi, Atefeh Entezari, Farhad Jadidi-Niaragh, Saeed Solali
BIOMEDICINE & PHARMACOTHERAPY
(2018)
Review
Cell Biology
Raedeh Saraei, Faroogh Marofi, Adel Naimi, Mehdi Talebi, Mahnaz Ghaebi, Naser Javan, Omid Salimi, Ali Hassanzadeh
JOURNAL OF CELLULAR PHYSIOLOGY
(2019)
Article
Oncology
Adel Naimi, Sahar Safaei, Atefeh Entezari, Saeed Solali, Ali Hassanzadeh
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2020)
Review
Cell Biology
Shirin Tavakoli, Hamid Reza Ghaderi Jafarbeigloo, Ali Shariati, Afsaneh Jahangiryan, Faezeh Jadidi, Mohammd Amin Jadidi Kouhbanani, Ali Hassanzadeh, Majid Zamani, Kamran Javidi, Adel Naimi
JOURNAL OF CELLULAR PHYSIOLOGY
(2020)
Review
Cell & Tissue Engineering
Faroogh Marofi, Marwan Mahmood Saleh, Heshu Sulaiman Rahman, Wanich Suksatan, Moaed E. Al-Gazally, Walid Kamal Abdelbasset, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Yashwant Pathak, Adel Naimi, Behzad Baradaran, Marzieh Nikoo, Farhad Motavalli Khiavi
Summary: CAR-NK cells are safer and more efficient than CAR-T cells in treating tumors, especially hematological malignancies. NK cells can be effectively engineered to express CARs with substantial cytotoxic activity against both hematological and solid tumors.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Raedeh Saraei, Heshu Sulaiman Rahman, Masoud Soleimani, Mohammad Asghari-Jafarabadi, Adel Naimi, Ali Hassanzadeh, Saeed Solali
Summary: The study found that kaempferol can enhance the cytotoxic and pro-apoptotic effects of TRAIL on CML cells by regulating the expression of specific genes, providing a new approach for leukemia therapy.
MOLECULAR BIOLOGY REPORTS
(2022)
Review
Medicine, General & Internal
Maryam Koupaei, Adel Naimi, Narges Moafi, Paria Mohammadi, Faezeh Sadat Tabatabaei, Soroosh Ghazizadeh, Mohsen Heidary, Saeed Khoshnood
Summary: This study found that the coinfection of TB and COVID-19 can increase mortality rates. The respiratory symptoms of both diseases are very similar, leading to misdiagnosis, and TB is sometimes diagnosed later than COVID-19, resulting in worsened disease severity, especially in those with underlying conditions. Hence, regular screening of TB patients is crucial in the COVID-19 era to prevent the spread of TB/COVID-19 coinfection.
FRONTIERS IN MEDICINE
(2021)
Article
Pediatrics
Yoda Yaghoubi, Ali Hassanzadeh, Adel Naimi, Sepehr Abdolahi, Mehdi Yousefi, Leili Aghebati-Maleki, Majid Zamani
Summary: This study aimed to assess the effects of platelet lysate (PL) on UCB CD34(+) cell expansion and megakaryocyte differentiation. The results showed that PL can enhance UCB CD34+ cell expansion, increase CD41 expression, and upregulate the expression of specific genes involved in megakaryocyte differentiation compared to fetal bovine serum (FBS).
IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2021)
Article
Genetics & Heredity
Yoda Yaghoubi, Majid Zamani, Adel Naimi, Ali Hassanzadeh, Nastaran Gharibeh, Javad Madani, Roza Motevali, Aylin Nikshad, Afsoon Aghlmandi, Forough Parhizkar, Amir Mehdizadeh, Mehdi Nazari, Mehdi Yousefi, Ali Akbar Movassaghpour
Article
Oncology
Ali Hassanzadeh, Adel Naimi, Majid F. Hagh, Raedeh Saraei, Faroogh Marofi, Saeed Solali
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2019)
Article
Pharmacology & Pharmacy
Majid Zamani, Yoda Yaghoubi, Adel Naimi, Ali Hassanzadeh, Ramin Pourakbari, Leili Aghebati-Maleki, Roza Motavalli, Afsoon Aghlmandi, Amir Mehdizadeh, Mehdi Nazari, Mehdi Yousefi, Ali Akbar Movassaghpour
Summary: The study found that platelet lysate (PL) can enhance the proliferation and differentiation of CD34(+) HSCs, suggesting it as a suitable alternative in culture medium and HSCs differentiation.
ADVANCED PHARMACEUTICAL BULLETIN
(2021)